2021 Year in Review - Gastrointestinal Cancer

This edition of Year in Review is focused on gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) cancer, and immunotherapy and targeted therapies used in the management of these cancers. Read More ›

Nivolumab combined with chemotherapy had improved survival outcomes and an acceptable safety profile in patients with advanced gastric/esophageal cancer, according to CheckMate-649 study results. Read More ›

DKN-01 plus tislelizumab and CAPOX combination demonstrates promising response rates and safety data in phase 2a study. Read More ›

Results from the CheckMate-648 study demonstrate that nivolumab added to either ipilimumab or chemotherapy improves overall survival in patients with advanced esophageal squamous-cell carcinoma. Read More ›

Recently released positive findings from the LEAP-005 trial of lenvatinib plus pembrolizumab in the treatment of previously treated gastric cancer leads to cohort expansion. Read More ›

Second-line or later nivolumab monotherapy yields no clear evidence of efficacy advantage for patients with advanced esophageal cancer. Read More ›

CheckMate-577 clinical trial results show nivolumab adjuvant therapy increases disease-free survival over placebo in patients with gastroesophageal junction (GEJ) cancer or esophageal cancer. Read More ›

No survival advantage was observed with durvalumab use in the PLATFORM clinical trial, but a patient subgroup was observed to have a radiological response. Read More ›

The dose-escalation phase of the EMERGE clinical trial results show that 200 mg domatinostat twice daily is safe and efficacious. Read More ›

Avelumab maintenance therapy conveys no overall survival difference over the use of continued chemotherapy in patients with advanced GEJC or gastric cancer. Read More ›

Page 1 of 3

Subscribe Today!

To sign up for our free e-Newsletter or print publications, please enter your contact information below.

I'd like to receive:

OPM e-Newsletter
OPM print publication